Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001193125-24-272445
Filing Date
2024-12-06
Accepted
2024-12-06 16:05:56
Documents
18
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q/A d864210d10qa.htm   iXBRL 10-Q/A 59570
2 EX-31.1 d864210dex311.htm EX-31.1 3469
3 EX-31.2 d864210dex312.htm EX-31.2 3369
  Complete submission text file 0001193125-24-272445.txt   397667

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA spry-20240930.xsd EX-101.SCH 6063
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE spry-20240930_cal.xml EX-101.CAL 952
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE spry-20240930_def.xml EX-101.DEF 16653
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE spry-20240930_lab.xml EX-101.LAB 22119
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE spry-20240930_pre.xml EX-101.PRE 17664
20 EXTRACTED XBRL INSTANCE DOCUMENT d864210d10qa_htm.xml XML 28340
Mailing Address 11682 EL CAMINO REAL, SUITE 120 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL, SUITE 120 SAN DIEGO CA 92130 858-771-9307
ARS Pharmaceuticals, Inc. (Filer) CIK: 0001671858 (see all company filings)

EIN.: 811489190 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q/A | Act: 34 | File No.: 001-39756 | Film No.: 241532299
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)